DE602004022205D1 - Pharmazeutische zusammensetzung für die verzögerte freisetzung von hydralazin und ihre verwendung als unterstützung zur krebstherapie - Google Patents

Pharmazeutische zusammensetzung für die verzögerte freisetzung von hydralazin und ihre verwendung als unterstützung zur krebstherapie

Info

Publication number
DE602004022205D1
DE602004022205D1 DE602004022205T DE602004022205T DE602004022205D1 DE 602004022205 D1 DE602004022205 D1 DE 602004022205D1 DE 602004022205 T DE602004022205 T DE 602004022205T DE 602004022205 T DE602004022205 T DE 602004022205T DE 602004022205 D1 DE602004022205 D1 DE 602004022205D1
Authority
DE
Germany
Prior art keywords
hydralazine
support
pharmaceutical composition
cancer therapy
delayed release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004022205T
Other languages
English (en)
Inventor
Flores Luis Estrada
Gonzalez Alfonso Duenas
Garcia Arturo Borbolla
Martinez Raul Serna
Hernandez Alfredo Rivera
Betancourt Alejandro Mohar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PSICOFARMA de C V SA
Original Assignee
PSICOFARMA de C V SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PSICOFARMA de C V SA filed Critical PSICOFARMA de C V SA
Publication of DE602004022205D1 publication Critical patent/DE602004022205D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE602004022205T 2004-09-09 2004-09-09 Pharmazeutische zusammensetzung für die verzögerte freisetzung von hydralazin und ihre verwendung als unterstützung zur krebstherapie Expired - Lifetime DE602004022205D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2004/000064 WO2006028362A1 (es) 2004-09-09 2004-09-09 Composición farmacéutica de liberación prolongada de hidralazina y su uso como apoyo para el tratamiento del cáncer

Publications (1)

Publication Number Publication Date
DE602004022205D1 true DE602004022205D1 (de) 2009-09-03

Family

ID=36036613

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004022205T Expired - Lifetime DE602004022205D1 (de) 2004-09-09 2004-09-09 Pharmazeutische zusammensetzung für die verzögerte freisetzung von hydralazin und ihre verwendung als unterstützung zur krebstherapie

Country Status (17)

Country Link
US (1) US7820200B2 (de)
EP (1) EP1803447B1 (de)
JP (1) JP4814885B2 (de)
CN (1) CN101039661A (de)
BR (1) BRPI0419032B8 (de)
CA (1) CA2579220C (de)
CR (1) CR9035A (de)
CY (1) CY1110508T1 (de)
DE (1) DE602004022205D1 (de)
DK (1) DK1803447T3 (de)
ES (1) ES2330227T3 (de)
MX (1) MX2007002871A (de)
NZ (1) NZ554360A (de)
PL (1) PL1803447T3 (de)
PT (1) PT1803447E (de)
SI (1) SI1803447T1 (de)
WO (1) WO2006028362A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4521402A (en) * 1983-01-03 1985-06-04 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of hydrazine
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8624213D0 (en) * 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
EP1611881A1 (de) * 1999-03-31 2006-01-04 Janssen Pharmaceutica N.V. Vorgelatinierte Stärke in einer Formulierung mit gesteuerter Freigabe
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
AU2003301654A1 (en) * 2002-10-22 2004-05-13 Dainippon Pharmaceutical Co., Ltd. Stabilized composition

Also Published As

Publication number Publication date
MX2007002871A (es) 2007-04-23
JP2008512450A (ja) 2008-04-24
BRPI0419032B8 (pt) 2021-05-25
CR9035A (es) 2009-03-27
SI1803447T1 (sl) 2010-01-29
PT1803447E (pt) 2009-08-14
US20090042889A1 (en) 2009-02-12
CA2579220A1 (en) 2006-03-16
CA2579220C (en) 2013-01-08
CY1110508T1 (el) 2015-04-29
WO2006028362A1 (es) 2006-03-16
DK1803447T3 (da) 2009-10-12
ES2330227T3 (es) 2009-12-07
CN101039661A (zh) 2007-09-19
BRPI0419032B1 (pt) 2019-02-05
BRPI0419032A (pt) 2007-12-11
JP4814885B2 (ja) 2011-11-16
EP1803447B1 (de) 2009-07-22
US7820200B2 (en) 2010-10-26
NZ554360A (en) 2009-11-27
PL1803447T3 (pl) 2010-05-31
EP1803447A1 (de) 2007-07-04

Similar Documents

Publication Publication Date Title
IL183583A (en) Quinazoline History and Pharmaceuticals Containing Them and Methods of Manufacturing
ZA200711085B (en) Processes for the manufacture of rosuvastatin and intermediates
HK1077583A1 (en) Cudr as biomarker for cancer progression and therapeutic response
IL180657A0 (en) Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases
IL188712A0 (en) Novel anti-igf-ir antibodies and uses thereof
IL181025A0 (en) Novel anti-igf-ir antibodies and uses thereof
ATE502960T1 (de) Lingo bindende moleküle und pharmazeutische verwendung davon
IL186071A0 (en) Antibodies against ccr5 and uses thereof
ATE428710T1 (de) Substituierte phenylaminothiazole und ihre verwendung
TWI367932B (en) Fluorescence material and manufacture thereof
PT2343320T (pt) Anticorpos anti-gitr e as suas utilizações
ATE493396T1 (de) Neue indazolcarboxamide und ihre verwendung
IL181608A0 (en) Cancer combination therapy comprising azd2171 and imatinib
IL190522A (en) A medicinal product containing hydrocarbon testosterone gel and use of testosterone to make the preparation
DE602006019611D1 (de) Neues künstliches basenpaar und verwendung davon
EP1978034A4 (de) Antiperiostin-antikörper und pharmazeutische zusammensetzung zur prävention oder behandlung von mit periostin in zusammenhang stehenden krankheiten, die diese enthält
EP1937816A4 (de) Marker zur krebsdiagnose und verwendung davon
HK1080397A1 (en) An acrylic acid-based binder composition and the pharmaceutical composition and transdermal therapeutic system thereof
GB0516069D0 (en) Pharmaceutical and use thereof
DE602007005372D1 (de) Zweischichtige tablette zur verhinderung von kardiovaskulären ereignissen
DE602006004713D1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
DE602006009296D1 (de) Oligopeptide und ihre verwendung
EP1951681A4 (de) Neue 2-aminopyrimidinderivate und deren verwendung
WO2006026027A8 (en) Markers of alterations in the y chromosome and uses therefor
DE602006013009D1 (de) Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition